Literature DB >> 19286478

What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment?

Peter Bytzer1.   

Abstract

BACKGROUND & AIMS: Despite the efficacy of proton pump inhibitors (PPIs) as therapeutics for patients with gastroesophageal reflux disease (GERD) in randomized controlled trials, a number of studies have shown that a proportion of patients with GERD are not satisfied with their treatment. This article reviews the possible reasons why patients are dissatisfied with the way their disease is managed.
METHODS: Studies published between 1970 and 2007 were identified from PubMed, EMBASE, and the author's existing database. The 2708 publications were reviewed, and irrelevant ones were excluded. Eleven studies were found to be appropriate for use in this review.
RESULTS: Patients who are given prescriptions for PPIs tend to be more satisfied than those given H(2)-receptor antagonists. Partial responders are likely to be more dissatisfied than patients whose symptoms are fully resolved. A decrease in health-related quality of life is associated with greater dissatisfaction. Patients are more likely to be satisfied if they are taken seriously by their physician and if their symptoms are investigated. They are also more likely to be satisfied if the patient-physician consultation is interactive.
CONCLUSIONS: Patient satisfaction is a complex issue that depends on many factors. Patient satisfaction can be influenced by treatment regimen, general level of well-being, the bedside manner of the physician, and the quality of patient-physician communication. Improvements in recognition of GERD can improve management of the disease as well as patient satisfaction with their care and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286478     DOI: 10.1016/j.cgh.2009.03.006

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

1.  Treatment of GORD: Three decades of progress and disappointments.

Authors:  Jean Paul Galmiche; Frank Zerbib; Stanislas Bruley des Varannes
Journal:  United European Gastroenterol J       Date:  2013-06       Impact factor: 4.623

Review 2.  Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review.

Authors:  Sander Jo van Zanten; Catherine Henderson; Nesta Hughes
Journal:  Can J Gastroenterol       Date:  2012-04       Impact factor: 3.522

Review 3.  Patient Values and Preferences Surrounding Proton Pump Inhibitor Use: A Scoping Review.

Authors:  Wade Thompson; Cody Black; Vivian Welch; Barbara Farrell; Lise M Bjerre; Peter Tugwell
Journal:  Patient       Date:  2018-02       Impact factor: 3.883

4.  Epidemiology of upper gastrointestinal symptoms in Brazil (EpiGastro): a population-based study according to sex and age group.

Authors:  Maria do Rosário Dias de Oliveira Latorre; Aline Medeiros da Silva; Décio Chinzon; Jaime N Eisig; Telma R P Dias-Bastos
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

5.  More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.

Authors:  Motoyasu Kusano; Hiroko Hosaka; Osamu Kawamura; Akiyo Kawada; Shiko Kuribayashi; Yasuyuki Shimoyama; Hidetoshi Yasuoka; Masafumi Mizuide; Taku Tomizawa; Toshihiko Sagawa; Ken Sato; Masanobu Yamada
Journal:  J Gastroenterol       Date:  2014-06-12       Impact factor: 7.527

6.  Dynamics of quality of life improvement after floppy Nissen fundoplication for gastroesophageal reflux disease.

Authors:  Jarek Kobiela; Łukasz Kaska; Magdalena Pindel; Arkadiusz Szarmach; Maria Janiak; Monika Proczko-Markuszewska; Tomasz Stefaniak; Dariusz Łaski; Andrzej Łachiński; Zbigniew Śledziński
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2015-09-16       Impact factor: 1.195

Review 7.  Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.

Authors:  Kentaro Sugano
Journal:  Therap Adv Gastroenterol       Date:  2018-01-09       Impact factor: 4.409

8.  Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.

Authors:  Yasuhiko Gotoh; Emiko Ishibashi; Shunichiro Honda; Tomohisa Nakaya; Chishio Noguchi; Koichi Kagawa; Kazunari Murakami
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.